Interius BioTherapeutics

Interius BioTherapeutics is a private, pre-clinical-stage biotech developing a novel platform for in vivo genetic medicine delivery. Its core innovation is a programmable lentiviral vector system that can be administered intravenously to genetically modify a patient's own cells inside the body, eliminating the need for complex ex vivo cell manufacturing and pre-conditioning chemotherapy. The company, now part of Kite Pharma (a Gilead company), is advancing a pipeline of in vivo CAR-T candidates and other genetic medicines with the goal of making these transformative treatments broadly accessible. Interius was founded based on direct clinical experience to address the critical limitations of current cell therapy logistics and patient access.

Proprietary LENTIVECTOR platform: a modular, programmable lentiviral vector system for targeted in vivo delivery of genetic payloads (e.g., CAR genes) via single IV infusion, enabling off-the-shelf, chemotherapy-free cell therapies.

Interius competes in the advanced cell therapy space against developers of allogeneic (off-the-shelf) CAR-Ts (e.g., Allogene, Caribou Biosciences) and other in vivo gene delivery platforms using viral vectors (e.g., lentivirus, AAV) or non-viral methods (e.g., lipid nanoparticles). Its key differentiation is the combination of in vivo administration, lentiviral delivery for stable integration, and the elimination of preconditioning chemo. Kite's backing provides a significant competitive advantage in resources and commercialization expertise.